Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke

Thrombolytic stroke therapy with tissue plasminogen activator (tPA) is limited by risks of hemorrhagic transformation (HT). We have reported that a new 12/15‐lipoxygenase (12/15‐LOX) inhibitor ML351 reduced tPA related HT in mice subjected to experimental stroke under anticoagulation. In this study, we asked whether ML351 can ameliorate tPA induced HT in an embolic stroke model. Rats were subjected to embolic middle cerebral artery occlusion with 2 or 3 hr ischemia and tPA infusion, with or without ML351. Regional cerebral blood flow was monitored 2 hr after ischemia and continuously monitored for 1 hr after treatment for determining reperfusion. Hemoglobin was determined in brain homogenates and infarct volume was quantified at 24 hr after stroke.12/15‐LOX, cluster of differentiation 68(CD68), immunoglobulin G (IgG), and tight junction proteins expression was detected by immunohistochemistry. ML351 significantly reduced tPA related hemorrhage after stroke without affecting its thrombolytic efficacy. ML351 also reduced blood–brain barrier disruption and improved preservation of junction proteins. ML351 and tPA combination improved neurological deficit of rats even though ML351 did not further reduce the infarct volume compared to tPA alone treated animals. Pro‐inflammatory cytokines were suppressed by ML351 both in vivo and in vitro experiments. We further showed that ML351 suppressed the expression of c‐Jun‐N‐terminal kinase (JNK) in brains and microglia cultures, whereas exogenous 12‐HETE attenuated this effect in vitro. In conclusion, ML351 and tPA combination therapy is beneficial in ameliorating HT after ischemic stroke. This protective effect is probably because of 12/15‐LOX inhibition and suppression of JNK‐mediated microglia/macrophage activation.

[1]  John H. Zhang,et al.  DKK3 attenuates JNK and AP-1 induced inflammation via Kremen-1 and DVL-1 in mice following intracerebral hemorrhage , 2019, Journal of Neuroinflammation.

[2]  Xuxia Wang,et al.  Microglia-derived TNF-α mediates endothelial necroptosis aggravating blood brain–barrier disruption after ischemic stroke , 2019, Cell Death & Disease.

[3]  Daishi Tian,et al.  Dual Functions of Microglia in Ischemic Stroke , 2019, Neuroscience Bulletin.

[4]  Ligong Lu,et al.  Astrocytic cytochrome P450 4A/20-hydroxyeicosatetraenoic acid contributes to angiogenesis in the experimental ischemic stroke , 2019, Brain Research.

[5]  E. Lo,et al.  Impact of 12/15-Lipoxygenase on Brain Injury After Subarachnoid Hemorrhage , 2019, Stroke.

[6]  Huijuan Jin,et al.  The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe? , 2019, Cellular and Molecular Life Sciences.

[7]  Zhiping Hu,et al.  HSPB8 over‐expression prevents disruption of blood–brain barrier by promoting autophagic flux after cerebral ischemia/reperfusion injury , 2018, Journal of neurochemistry.

[8]  John H. Zhang,et al.  Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β‐catenin pathway activation in a mouse model , 2018, Journal of neurochemistry.

[9]  Xiufang Li,et al.  Anti‐inflammatory effects of anisalcohol on lipopolysaccharide‐stimulated BV2 microglia via selective modulation of microglia polarization and down‐regulation of NF‐&kgr;B p65 and JNK activation , 2018, Molecular immunology.

[10]  Adam R Ferguson,et al.  Translational Stroke Research: Vision and Opportunities , 2017, Stroke.

[11]  E. Lo,et al.  Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats , 2017, Translational Stroke Research.

[12]  Shile Huang,et al.  Celastrol ameliorates Cd‐induced neuronal apoptosis by targeting NOX2‐derived ROS‐dependent PP5‐JNK signaling pathway , 2017, Journal of neurochemistry.

[13]  E. Lo,et al.  Increased 12/15-Lipoxygenase Leads to Widespread Brain Injury Following Global Cerebral Ischemia , 2017, Translational Stroke Research.

[14]  Jiao Sun,et al.  Blood-brain barrier dysfunction induced by silica NPs in vitro and in vivo: Involvement of oxidative stress and Rho-kinase/JNK signaling pathways. , 2017, Biomaterials.

[15]  Wenchao Liu,et al.  Baicalein Attenuates Neurological Deficits and Preserves Blood–Brain Barrier Integrity in a Rat Model of Intracerebral Hemorrhage , 2016, Neurochemical Research.

[16]  G. Mitchell,et al.  Mechanisms of microglial activation in models of inflammation and hypoxia: Implications for chronic intermittent hypoxia , 2016, The Journal of physiology.

[17]  D. Stein,et al.  Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats , 2015, Brain, Behavior, and Immunity.

[18]  J. Rokach,et al.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. , 2015, Biochimica et biophysica acta.

[19]  M. Chopp,et al.  Focal embolic cerebral ischemia in the rat , 2015, Nature Protocols.

[20]  Jian Wang,et al.  Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers , 2014, Molecular Neurobiology.

[21]  B. Manwani,et al.  Inhibition of mitogen-activated protein kinase phosphatase-1 (MKP-1) increases experimental stroke injury , 2014, Experimental Neurology.

[22]  Emiri T. Mandeville,et al.  Neuronal Production of Lipocalin-2 as a Help-Me Signal for Glial Activation , 2014, Stroke.

[23]  Adam Yasgar,et al.  Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies , 2014, Journal of medicinal chemistry.

[24]  Yulan Zhu,et al.  The protective effect of HET0016 on brain edema and blood–brain barrier dysfunction after cerebral ischemia/reperfusion , 2014, Brain Research.

[25]  R. Haynes,et al.  12/15-Lipoxygenase Expression Is Increased in Oligodendrocytes and Microglia of Periventricular Leukomalacia , 2013, Developmental Neuroscience.

[26]  J. Xu,et al.  Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease , 2013, Cell Death and Disease.

[27]  K. van Leyen,et al.  Lipoxygenase: an emerging target for stroke therapy. , 2013, CNS & neurological disorders drug targets.

[28]  M. Colado,et al.  A study on the effect of JNK inhibitor, SP600125, on the disruption of blood–brain barrier induced by methamphetamine , 2013, Neurobiology of Disease.

[29]  E. Lo,et al.  Inhibition of 12/15‐lipoxygenase as therapeutic strategy to treat stroke , 2013, Annals of neurology.

[30]  Jun-hong Guan,et al.  Inhibition of c-Jun N-terminal kinase prevents blood–brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage , 2012, Acta Neurochirurgica.

[31]  Yulan Zhu,et al.  The protective effect of nordihydroguaiaretic acid on cerebral ischemia/reperfusion injury is mediated by the JNK pathway , 2012, Brain Research.

[32]  Marc Fisher,et al.  Visualization of Clot Lysis in a Rat Embolic Stroke Model: Application to Comparative Lytic Efficacy , 2011, Stroke.

[33]  R. Ji,et al.  Light touch induces ERK activation in superficial dorsal horn neurons after inflammation: involvement of spinal astrocytes and JNK signaling in touch‐evoked central sensitization and mechanical allodynia , 2010, Journal of neurochemistry.

[34]  E. Lo,et al.  Annexin A2 Combined with Low-Dose tPA Improves Thrombolytic Therapy in a Rat Model of Focal Embolic Stroke , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  K. Arai,et al.  Increased Nuclear Apoptosis-Inducing Factor after Transient Focal Ischemia: A 12/15-Lipoxygenase-dependent Organelle Damage Pathway , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  K. Arai,et al.  12/15‐Lipoxygenase targets neuronal mitochondria under oxidative stress , 2009, Journal of neurochemistry.

[37]  K. Arai,et al.  Protecting Against Cerebrovascular Injury: Contributions of 12/15-Lipoxygenase to Edema Formation After Transient Focal Ischemia , 2008, Stroke.

[38]  M. Woodward,et al.  Associations of Proinflammatory Cytokines With the Risk of Recurrent Stroke , 2008, Stroke.

[39]  Jiali Gu,et al.  The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. , 2007, Endocrinology.

[40]  K. Arai,et al.  Baicalein and 12/15-Lipoxygenase in the Ischemic Brain , 2006, Stroke.

[41]  S. Tsirka,et al.  Fibrin‐modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: A review , 2005, Glia.

[42]  T. Nabeshima,et al.  The role of tissue plasminogen activator in methamphetamine‐related reward and sensitization , 2005, Journal of neurochemistry.

[43]  K. Furie,et al.  Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke , 2004, Stroke.

[44]  E. Melamed,et al.  A low molecular weight copper chelator crosses the blood–brain barrier and attenuates experimental autoimmune encephalomyelitis , 2004, Journal of neurochemistry.

[45]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[46]  E. Lo,et al.  Antiactin-Targeted Immunoliposomes Ameliorate Tissue Plasminogen Activator-Induced Hemorrhage after Focal Embolic Stroke , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  E. Lo,et al.  Triggers and mediators of hemorrhagic transformation in cerebral ischemia , 2003, Molecular Neurobiology.

[48]  C. Siao,et al.  Tissue Plasminogen Activator Mediates Microglial Activation via Its Finger Domain through Annexin II , 2002, The Journal of Neuroscience.

[49]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[50]  M. Chopp,et al.  A New Rat Model of Thrombotic Focal Cerebral Ischemia , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  T. Holman,et al.  Contributions of 12/15-Lipoxygenase to Bleeding in the Brain Following Ischemic Stroke. , 2019, Advances in experimental medicine and biology.

[52]  E. Lo,et al.  12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke , 2017, Stroke.